ATLASMonte Rosa Therapeutics (GLUE) earnings date: Nov 5, 2026
Monte Rosa Therapeutics (GLUE) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, before the open. Analysts expect EPS of -$0.10.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on GLUE
| Last price | $10.61 (-1.4%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.8% |
| Earnings beat history | Beat the EPS estimate in 0 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Monte Rosa Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Monte Rosa Therapeutics reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Monte Rosa Therapeutics. You can switch it off at any time.
Alert me before GLUE reportsFree to start. Creating an account takes under a minute.
Notify me when Monte Rosa Therapeutics reports
Track GLUE free Add Monte Rosa Therapeutics to a free ATLAS watchlist and see its next report date in one place.
GLUE earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.10 |
| Last report | Aug 6, 2026 · Miss |
| Beat rate (last 5 reports) | 0 of 5 (0%) |
| Average EPS surprise | -102.1% |
| Average move around a report | ±3.2% (last 5) |
| Sector | Healthcare · Biotechnology |
Monte Rosa Therapeutics earnings history: last 5 reports
Monte Rosa Therapeutics last reported on Aug 6, 2026: EPS of -$0.43 against an estimate of -$0.37 (-16.2% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 6, 2026 | -$0.37 | -$0.43 | -16.2% | Miss | +1.7% |
| May 7, 2026 | -$0.38 | -$0.45 | -18.4% | Miss | -4.9% |
| Mar 17, 2026 | -$0.34 | -$0.55 | -61.8% | Miss | -3.6% |
| Jan 30, 2026 | $0.42 | $0.36 | -14.3% | Miss | -2.3% |
| Dec 5, 2025 | -$0.02 | -$0.10 | -400.0% | Miss | +3.4% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for GLUE
See the fair value, the probability range and the earnings history of Monte Rosa Therapeutics on its ATLAS page.
Monte Rosa Therapeutics (GLUE) stock analysisPlans from €3.99 a month.
Monte Rosa Therapeutics earnings: frequently asked questions
When does Monte Rosa Therapeutics (GLUE) report earnings?
Monte Rosa Therapeutics is scheduled to report on Thursday, November 5, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for GLUE?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.10 per share (USD). Estimates can change before the report.
How often does GLUE beat earnings estimates?
Of its last 5 reports with a recorded result, Monte Rosa Therapeutics beat the EPS estimate 0 times; the average surprise was -102.1%. Past results do not predict the next one.
How much does GLUE move around earnings?
Over its last 5 reports the stock moved an average of 3.2% (absolute, from the close before the report day to the close after it), and finished higher 2 of 5 times.
Did Monte Rosa Therapeutics beat earnings estimates last quarter?
Monte Rosa Therapeutics last reported on Aug 6, 2026: EPS of -$0.43 against an estimate of -$0.37 (-16.2% surprise), a miss.
How much does GLUE usually move in a day?
On a normal trading day the ATLAS model puts GLUE’s one-day range at about ±3.8%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer